Investment Banks Initiate Coverage of Veracyte | GenomeWeb

NEW YORK (GenomeWeb News) – Two investment banks today initiated coverage of Veracyte with Outperform ratings on the company's stock.

The coverage initiation by Cowen & Co., and Leerwink Swann follows Veracyte's announcement on Monday that revenues for its third quarter rose 75 percent year over year, as well as the South San Francisco, Calif.-based company's initial public offering earlier this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.